Trial Court Judgment for Amneal in Litigation over Hyperparathyroidism Drug
Represented Amneal Pharmaceuticals LLC in a Hatch-Waxman patent litigation through trial concerning a drug for treating secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis. Secured judgment of non-infringement from District Court after five-day trial. Amgen Inc. v. Amneal Pharms. LLC, 16-0853-GMS (consolidated) (D. Del.). The Federal Circuit reversed and remanded for further proceedings in the trial court.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.